Navigation Links
New Scientists Boost Disease-based Research at Boston Biomedical Research Institute
Date:9/27/2007

Seven new hires are fruits of strategic plan

WATERTOWN, Mass., Sept. 27 /PRNewswire/ -- Beginning a new era of growth and discovery, Boston Biomedical Research Institute, an independent not-for- profit biomedical research institute located in Watertown, MA, has recruited seven new scientists, a 23% increase in its scientific staff.

The seven newly hired scientists are the fruits of a three-year strategic planning process designed to refine the Institute's basic research agenda into four core areas -- Cancer, Cardiovascular Disease, Regenerative Biology and Degenerative Disease, and Proteomics. "These core initiatives build upon the Institute's existing scientific strengths in protein-based basic research which uses disease models to find powerful new therapeutics for a range of illnesses, including cancer, Alzheimer's disease, stroke, and muscular dystrophy, among others," says Institute Director, Dr. Charles P. Emerson, Jr.

The new scientists include Dr. James L. Sherley who is studying adult stem cells with relevance to a range of problems associated with aging and how cancer forms; Dr. Shinichi Takayama who is researching a family of proteins known as BAG which plays a role in muscle degeneration and cancer, and is key to cell movement; Dr. Martin Duennwald and Dr. Moonkyoung Um and their collaborative research in the area of neurodegenerative diseases such as Alzheimer's, Parkinson's and Huntington's diseases; Dr. Oliver King who will begin a new program in computational biology at BBRI, and whose research involves understanding the evolution of proteins involved in neurodegenerative disorders; Dr. Kent Nybakken who is studying the function of a key signaling pathway, the Hedgehog pathway, which is important in normal development, stem cell regulation and cancer; and Dr. Sachiko Homma whose studies focus on sarcopenia, which is the loss of muscle mass that occurs with aging.

"By hiring new scientists in these key areas, the Institute is making a strong commitment to maximizing the potential for new collaborations that will ultimately lead to more significant and frequent discoveries," said board president, Mr. John R. Layton, "The Institute's ability to attract such talent is testament to the quality of science already underway here, and the new scientists recognize the benefits of the uniquely interactive environment for discovery that we actively foster."

In addition to attracting and developing new scientific talent, the Institute plans to broaden partnerships with laboratories at local universities and research institutes to further enhance its studies. "The selection of this impressive slate of scientists underscores BBRI's commitment to building successful collaborations both within and outside the Institute," said Dr. Emerson.

"The hiring of these exceptionally talented scientists will strengthen BBRI's efforts in conducting the most innovative research possible," said Dr. Judah Folkman, noted cancer researcher and Trustee of Boston Biomedical. "Under the leadership of Dr. Emerson, with his proven track record of innovation and his passion for disease-based research, this talented constellation of new scientific staff will enable BBRI to have an even greater impact on improving the health of people around the world."

"BBRI has emerged as a very innovative institution for collaborative disease research. The newly hired scientists possess a stellar combination of scientific brilliance, technical excellence, and collaborative savvy, and they are very enthusiastic about the unique research environment that BBRI provides," said Dr. Folkman. "These scientists promise to do great things for BBRI and for human health."

About Boston Biomedical Research Institute

Founded in 1968, Boston Biomedical Research Institute is a not-for-profit basic research institute dedicated to the understanding, treatment and prevention of a wide range of human diseases and conditions including cancer, cardiovascular diseases, neural and neuromuscular diseases, and degenerative diseases. For more information visit http://www.bbri.org

Media Contact: Elizabeth M. Erickson, 617-658-7707 or erickson@bbri.org


'/>"/>
SOURCE Boston Biomedical Research Institute
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. UW computer scientists fighting computer virus "Cold War"
2. Scientists find way to make human collagen in lab
3. Wisconsin scientists to be recognized for innovative biofuel technology
4. UW-Madison scientists to mimic nature for newest cancer drugs
5. UW scientists study strange material with communications potential
6. Scientists find nanotech method for examining cells
7. UW space scientists use Keck telescope to study wild weather of Uranus
8. UW computer scientists tout achievements and explain industry shortcomings
9. Facing shortage of U.S. scientists, UW wants to boost math enrollment
10. UW-Madison scientists find a key to cell division
11. TIP/UW Scientists Provide Mars Rover Commentary
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 23, 2016  Blueprint Bio, a company dedicated to ... medical community, has closed its Series A funding round, ... "We have received a commitment from Forentis ... need to meet our current goals," stated Matthew ... runway to complete validation on the current projects in ...
(Date:6/23/2016)... -- On Wednesday, June 22, 2016, the NASDAQ ... Dow Jones Industrial Average edged 0.27% lower to finish at ... Stock-Callers.com has initiated coverage on the following equities: Infinity Pharmaceuticals ... NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ ... Learn more about these stocks by accessing their free trade ...
(Date:6/23/2016)... ... 23, 2016 , ... Regulatory Compliance Associates® Inc. (RCA), a ... webinar on Performing Quality Investigations: Getting to Root Cause. This ... charge. , Incomplete investigations are still a major concern to the Regulatory Authorities ...
(Date:6/23/2016)... June 22, 2016  Amgen (NASDAQ: AMGN ... QB3@953 life sciences incubator to accelerate the ... shared laboratory space at QB3@953 was created to help ... obstacle for many early stage organizations - access to ... sponsorship, Amgen launched two "Amgen Golden Ticket" awards, providing ...
Breaking Biology Technology:
(Date:4/28/2016)... April 28, 2016 First quarter 2016:   ... 966% compared with the first quarter of 2015 The ... 589.1 M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) ... guidance is unchanged, SEK 7,000-8,500 M. The operating margin ...
(Date:4/15/2016)... , April 15, 2016 ... the,  "Global Gait Biometrics Market 2016-2020,"  report to ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,The global gait biometrics ... of 13.98% during the period 2016-2020. ... angles, which can be used to compute factors ...
(Date:3/29/2016)... March 29, 2016 LegacyXChange, Inc. ... "LEGX" and SelectaDNA/CSI Protect are pleased to announce our ... in a variety of writing instruments, ensuring athletes signatures ... created collectibles from athletes on LegacyXChange will be assured ... the DNA. Bill Bollander , CEO ...
Breaking Biology News(10 mins):